Get started

Usstocks

Investing in Cybersecurity: PANW vs CRWD vs FTNT◉ Abstract The cybersecurity landscape is rapidly evolving, with emerging threats and innovative solutions driving growth in the industry. This article examines the competitive dynamics between three leading cybersecurity stocks: Palo Alto Networks (PANW), CrowdStrike (CRWD), and Fortinet (FTNT). As these companies sprint to become the top cybersecurity provider, we analyse their strengths, weaknesses, and strategies for success. ◉ Global Cybersecurity Market Overview The global cybersecurity market has experienced significant growth and is projected to continue expanding in the coming years. As of 2023, the market was valued at approximately USD 192.4 billion and is expected to reach between USD 501 billion and USD 608 billion by 2033, with compound annual growth rates (CAGR) ranging from 9% to 12% depending on the source and forecast period considered. ◉ Growth Drivers 1. Increasing Cyber Threats: The frequency and sophistication of cyber-attacks, including ransomware and data breaches, are rising, prompting organizations to enhance their security measures. 2. Digital Transformation: The rapid adoption of digital technologies, such as cloud computing and the Internet of Things (IoT), expands the attack surface and necessitates robust cybersecurity solutions. 3. Regulatory Compliance: Stricter regulations regarding data protection, like GDPR and CCPA, compel organizations to invest in cybersecurity to ensure compliance and protect sensitive information. 4. Proliferation of Smart Devices: The increasing use of connected devices in homes and industries creates more entry points for cyber threats, driving demand for advanced security solutions. 5. E-commerce Growth: The rise in online transactions increases the need for secure payment systems and data protection, further fuelling the cybersecurity market. Remote Work Trends: The shift towards remote work has heightened the need for secure remote access solutions to protect organizational data from cyber threats. ◉ Regional Insights ● North America: This region dominates the global cybersecurity market, accounting for over 36% of the market share. The presence of major tech firms and a high incidence of cyber threats contribute to its leadership position. ● Europe: The European market is also growing rapidly due to increased digital transformation efforts and regulatory pressures that emphasize data security. ● Asia-Pacific: Expected to exhibit the fastest growth rate during the forecast period, driven by industrialization, rising internet penetration, and awareness of cybersecurity risks. ◉ Major Players in the Cybersecurity Market 1. Palo Alto Networks NASDAQ:PANW - $132.7 B 2. CrowdStrike Holdings NASDAQ:CRWD - $89.7 B 3. Fortinet NASDAQ:FTNT - $75.26 B In this comparative analysis we are focused to provide a detailed understanding of the competitive dynamics of three cybersecurity giants: Palo Alto Networks, CrowdStrike Holdings, and Fortinet. ◉ Company Overviews ● Palo Alto Networks Palo Alto Networks, Inc. is a leading provider of cybersecurity solutions worldwide. The company offers a range of products and services, including network security platforms, cloud security solutions, security operation solutions, subscription services, and professional services. Headquartered in Santa Clara, California, Palo Alto Networks was incorporated in 2005 and has since become a trusted partner for organizations seeking to protect themselves from cyber threats. ● CrowdStrike Holdings CrowdStrike provides cloud-delivered cybersecurity solutions, offering endpoint, cloud workload, identity, and data protection. Its Falcon platform provides various security services, including threat intelligence, vulnerability management, and AI-powered workflow automation. Headquartered in Austin, Texas, CrowdStrike was incorporated in 2011. ● Fortinet Fortinet, Inc. was founded in 2000 and is headquartered in Sunnyvale, California. The company provides comprehensive cybersecurity and converged networking and security solutions worldwide. Its offerings include secure networking solutions, network firewall solutions, wireless LAN solutions, and secure connectivity solutions. Additionally, Fortinet provides Unified SASE solutions, security operations solutions, and a range of security services and support. The company serves a diverse customer base, including enterprises, service providers, governments, and small and medium-sized businesses. ◉ Strategic Growth Initiatives of Leading Cybersecurity Players ● Palo Alto Networks 1. Platformization: Transitioning from a traditional firewall vendor to a comprehensive cybersecurity platform provider, offering a wider range of security solutions. 2. Next-Generation Security: Continuing to deliver advanced security solutions to address evolving cyber threats. ● CrowdStrike 1. Innovation: Leveraging AI-powered capabilities to enhance the Falcon platform and maintain a competitive edge in the cybersecurity market. 2. Expansion: Expanding into adjacent markets, such as cloud security and identity protection, to broaden its customer base and product offerings. ● Fortinet 1. "Rule of 45" Framework: Adhering to the "Rule of 45" framework to balance revenue growth with profitability, ensuring a sustainable business model. 2. Product Refresh Cycle: Implementing a strategic product refresh cycle to drive upgrade activity among existing customers and stimulate revenue growth. ◉ Technical Standings ● Palo Alto Networks ➖ The stock has been on a strong upward trajectory, marked by a consistent pattern of higher highs and higher lows. ➖ Following a significant breakout last month, it is currently trading at an all-time high, with expectations for further increases. ● CrowdStrike Holdings ➖ In general, this stock is trending upward, although it has faced considerable price volatility over an extended period. ➖ After reaching an all-time high close to the 400 mark, it underwent a sharp correction. However, the stock is now climbing again and nearing its previous peak. ● Fortinet ➖ This stock had undergone a lengthy consolidation phase lasting nearly three years, resulting in the development of a Broadening pattern. ➖ After a recent breakout, the price is now targeting new highs. ◉ Relative Strength ➖ The chart clearly demonstrates Fortinet's exceptional performance, showcasing an impressive return of nearly 88%. In comparison, Mastercard and Visa have generated returns of 53% and 41%, respectively. ◉ Revenue & Profit Analysis ● Palo Alto Networks ◾ Year-over-Year ➖ In FY24, Palo Alto Networks (PANW) celebrated an impressive revenue surge of 16.5%, achieving $8,027 million, a notable increase from $6,893 million in FY23. ➖ The EBITDA for FY24 also experienced a substantial boost, reaching $1,094 million, up from $590 million in FY23. ◾ Quarter-over-Quarter ➖ In the most recent October quarter, PANW reported revenues of $2,139 million, a slight dip from the $2,190 million recorded in July 2024. However, this still represents a year-over-year growth of nearly 14% from $1,878 million in the same quarter last year. ➖ The company also reported its highest-ever EBITDA of $413 million in October, an increase from $314 million in July 2024. Compared to the same quarter last year, this figure has risen by almost 20% from $279.5 million. ➖ In October, the diluted EPS rose to $7.69 (LTM), up from $7.28 (LTM) in July 2024, marking an extraordinary year-over-year increase of 333% from $1.78 (LTM). ● CrowdStrike ◾ Year-over-Year ➖ CrowdStrike (CRWD) saw a robust revenue growth of 36.3% in FY23, reaching $3,055 million, up from $2,241 million in FY22. ➖ Conversely, the EBITDA for FY24 has seen a decline, reporting $106 million, down from $118 million in FY23. ◾ Quarter-over-Quarter ➖ In the latest October quarter, CRWD's revenue rose to $1,010 million, compared to $964 million in July 2024. This reflects a year-over-year increase of nearly 28.5% from $786 million in the same quarter last year. ➖ The EBITDA for the most recent June quarter was $15.3 million, showing a significant drop from $52.4 million in July 2024. ➖ In October, the diluted EPS decreased to $0.51 (LTM), down from $0.69 (LTM) in July 2024. ● Fortinet ◾ Year-over-Year ➖ In fiscal year 2023, Fortinet reported a remarkable revenue increase of 20%, reaching $5,304 million, up from $4,417 million in fiscal year 2022. ➖ The EBITDA also saw a significant rise, with the 2023 fiscal year totaling $1,350 million, compared to $1,070 million the previous year. ◾ Quarter-over-Quarter ➖ In the latest September quarter, revenue continued to grow, hitting $1,508 million, an increase from $1,434 million in June 2024. This represents a substantial year-over-year growth of nearly 13% from $1,335 million. ➖ Furthermore, EBITDA for the September quarter neared $500 million, up from $465 million in the prior quarter, reflecting an impressive increase of nearly 51% from $330 million in the same quarter last year. ➖ The diluted earnings per share (EPS) also saw a significant increase in September, rising to $0.7 (LTM) from $0.5 (LTM) in June 2024, marking a notable jump of 70% compared to $0.41 (LTM) in the same quarter last year. ◉ Valuation ● P/E Ratio ➖ PANW stands at a P/E ratio of 48.6x. ➖ CRWD is at a P/E ratio of 707.9x. ➖ FTNT shows a P/E ratio of 49.2x. ◾ These numbers indicate that CRWD is considerably overvalued when compared to its competitors. ● P/B Ratio ➖ PANW's P/B ratio stands at 22.5x. ➖ CRWD's P/B ratio is 29.3x. ➖ On the other hand, FTNT's P/B ratio is significantly higher at 82.9x. ◾ FTNT's high P/B ratio may indicate overvaluation, but its asset-light business model reduces the significance of this metric. ● PEG Ratio ➖ PANW boasts a PEG ratio of 0.14. ➖ CRWD's PEG ratio is recorded at 0.66. ➖ FTNT, meanwhile, has a PEG ratio of 1.26. ◾ Analyzing the PEG ratios reveals that PANW is currently undervalued relative to its peers. ◉ Cash Flow Analysis ➖ PANW has achieved an impressive operating cash flow of $3,257 million for the fiscal year 2024, a substantial rise from $2,777 million in fiscal year 2023. ➖ In a similar vein, CRWD has also seen a positive trend in its operating cash flow, which has climbed to $1,166 million in fiscal year 2024, compared to $941 million the year before. ➖ Furthermore, FTNT has reported a remarkable increase in its operating cash flow, growing from $1,730 million in fiscal year 2022 to $1,935 million in fiscal year 2023. ◉ Debt Analysis ● Palo Alto Networks ➖ Debt to Equity Ratio: Approximately 0.1 as of October 2024, indicating a stable financial structure. ➖ Total Debt: About $645 million. ➖ Total Shareholder Equity: $5,911 million. ◾ PANW's ratio reflects a cautious debt approach, balancing equity and debt financing, with net debt well-supported by operating cash flow, enhancing financial stability. ● CrowdStrike ➖ Debt to Equity Ratio: Approximately 0.24. ➖ Total Debt: $743 million. ➖ Total Shareholder Equity: $3,096 million. ◾ CRWD's ratio suggests a thoughtful strategy regarding debt, maintaining a balance between equity and debt financing. ● Fortinet ➖ Debt to Equity Ratio: Approximately 1.1, indicating a significant level of debt relative to equity. ➖ Total Debt: $993 million. ➖ Total Shareholder Equity: $908 million. ◾ FTNT’s ratio shows a considerable reliance on debt financing, which can facilitate growth but also introduces risks related to interest obligations. ◉ Top Shareholders ● Palo Alto Networks ➖ The Vanguard Group has significantly increased its investment in Palo Alto Networks, now holding an impressive 9.13% stake, which marks a 1.53% rise from the last quarter. ➖ In comparison, Blackrock holds a notable 7.65% share in the company. ● CrowdStrike ➖ Turning to CrowdStrike, The Vanguard Group has also enhanced its position, elevating its ownership to an impressive 8.76%, reflecting a 1.84% increase since the previous quarter. ➖ Conversely, Blackrock possesses a considerable 7.35% stake. ● Fortinet ➖ Regarding Fortinet, The Vanguard Group commands a substantial 8.79% share in the firm. ➖ In contrast, Blackrock holds a 7.44% stake. ◉ Conclusion After conducting an exhaustive analysis of the major players in the cybersecurity sector, which included an in-depth look at both technical features and financial reports, we have determined that although Palo Alto Networks (PANW) might seem more appealing in terms of valuation, Fortinet (FTNT) stands out as the leading candidate in the industry due to its solid financials. Although concerns about debt exist, the company's strong cash reserves mitigate these worries significantly. On the other hand, CrowdStrike (CRWD) has faced a recent setback with an outage that has shaken investor trust, leading to a decline in its stock price and rendering it a less favourable investment option for the foreseeable future. Moreover, the cybersecurity sector is set to grow significantly due to rising cyber threats, fast-paced technology changes, and stricter regulations. Investors are advised to conduct thorough research, define clear investment goals, and maintain a long-term outlook to take advantage of this growth while minimizing risks.
NASDAQ:PANWLong
by NaranjCapital
12
Amazon Ignites: 150% Blaze Ahead?The stock has been in consolidation since August 2020, forming an Inverted Head & Shoulder pattern. Recently, it broke out above the neckline and is attempting to sustain above the 200 level. Currently trading at 210, the stock has the potential to surge to 500 levels in the next few years. However, the breakout lacks strong confirmation, as a significant bullish candle with volume expansion is absent. A crucial factor to watch is a monthly close above 200. This will help determine the stock's future trajectory and guide our trading and investment decisions.
NASDAQ:AMZNLong
by NaranjCapital
Corcept Therapeutics: A Shining Star in US BiotechCorcept Therapeutics is making waves in the booming U.S. biotech scene, with its stock surging 46.2% over the past six months. The company, known for its Cushing's syndrome drug, Korlym, reported a staggering 39.1% year-over-year sales increase, reaching $310.6 million in H1 2024. With a market cap of $4.42 billion, Corcept is actively developing new treatments like Relacorilant, which shows promise in clinical trials. Despite a high PE ratio of 35.3x compared to the industry average of 19x, its strong revenue growth and commitment to R&D position it as a solid investment opportunity in the fast-growing biotech market projected to reach $1,786 billion by 2033. ◉ The US Biotech Industry Outlook The biotech boom in the U.S. is hotter than a California summer! Fueled by groundbreaking tech and government cheerleading, the industry is soaring higher than a SpaceX rocket. According to Vision Research Reports, the market is projected to soar by 12.4% CAGR from 2024 to 2033. This rapid expansion is driven by advancements in areas like genomics, gene editing, and personalized medicine, positioning the U.S. as a global leader in healthcare innovation. ➖ The US biotechnology market size was valued at $552.43 billion in 2023 and is anticipated to hit around $1,786 billion by 2033. ➖ Key players like Abbvie Inc., Genentech Inc., and Amgen Inc. are leading the market. Acknowledging the remarkable expansion of the biotech sector, we are taking a closer look at a stock that is showing considerable strength in its technical chart, complemented by robust financial performance. ◉ Company Overview Corcept Therapeutics NASDAQ:CORT is a biopharmaceutical company dedicated to developing innovative treatments for severe endocrine, oncologic, and metabolic disorders. Their lead product, Korlym, is approved for Cushing's syndrome, a rare endocrine condition. Corcept is also advancing several pipeline candidates, including relacorilant for Cushing's syndrome, treatments for various cancers, and potential therapies for neurological conditions like amyotrophic lateral sclerosis and nonalcoholic steatohepatitis. Founded in 1998, Corcept is based in Menlo Park, California. ◉ Significant Stock Performance of Corcept Therapeutics Corcept Therapeutics Incorporated's stock price has risen 46.2% in the past six months, despite a 2% industry decline. This surge is attributed to strong demand for Korlym, the company's sole marketed drug used to treat Cushing's syndrome, a condition that is primarily cured with mifepristone. ◉ The Economic Impact of Korlym The primary source of revenue for Corcept emanates from the sales of Korlym. The drug has showcased remarkable growth, evidenced by a 39.1% year-over-year sales increase, culminating in $310.6 million during the first half of 2024. This growth is attributed to robust demand and an unprecedented number of patients being prescribed the medication. ◉ Corcept's Stock Growth Factors ● Potential of Relacorilant: Positive GRACE study results suggest relacorilant could be a valuable treatment for Cushing's syndrome, potentially driving revenue growth. ● Pipeline Diversification: Corcept's ongoing exploration of relacorilant in GRADIENT study demonstrates commitment to expanding pipeline. ● Regulatory Progress: Successful completion of GRACE study positions Corcept for a new drug application in late 2024. ● Market Need: Successful relacorilant could fill significant unmet medical need for Cushing's syndrome. Investent Advice by Naranj Capital Buy Corcept Therapeutics NASDAQ:CORT ● Buy Range- 38 - 40 ● Target- 55 - 58 ● Potential Return- 35% - 40% ● Invest Duration- 12-14 Months ◉ Market Capitalization - $4.42 B ◉ Peer Companies ● Prestige Consumer Healthcare NYSE:PBH - $3.644 B ● Jazz Pharmaceuticals NASDAQ:JAZZ - $6.766 B ● Amphastar Pharmaceuticals NASDAQ:AMPH - $2.423 B ● Organon NYSE:OGN - $5.142 B ◉ Relative Strength ➖ The chart distinctly demonstrates that NASDAQ:CORT has significantly surpassed the US Smallcap 2000 index, attaining an impressive annual return of 30%, marking a remarkable accomplishment. ◉ Technical Aspects ● Monthly Chart ➖ The historical chart shows that the stock price is trending upward, marked by a sequence of higher highs and higher lows. ➖ Having recently moved out of the parallel channel, the price is set for additional gains. ● Daily Chart ➖ After an extended period of consolidation, the stock price has formed an Inverted Head & Shoulders pattern. ➖ Post-breakout, the stock has stabilized above the breakout point and is now striving for new highs. ➖ A surge in trading volume suggests that buyers are currently showing significant interest. ◉ Revenue & Profit Analysis ● Year-on-year ➖ In the fiscal year 2023, revenue experienced a significant increase of 20.4%, amounting to $482.4 million, compared to $401.9 million in fiscal year 2022. ➖ However, EBITDA faced a downturn, decreasing to $108.3 million in FY23 from $113.9 million in FY22. ➖ The EBITDA margin also saw a reduction, falling to 22.46% from 28.34% in FY22. ➖ Moreover, diluted earnings per share (EPS) rose by 8% year-over-year, climbing to $0.94 in FY23, up from $0.87 in FY22. **While the growth in EBITDA might raise some concerns, it's crucial to acknowledge that the company is heavily investing in its research and development sector, and this investment has seen substantial increases over the years. ● Quarter-on-quarter ➖ In the most recent June quarter, the company reached an impressive achievement, with quarterly sales hitting a record high of $163.8 million. This represents a 12% increase from the $146.8 million reported in the March quarter and a substantial 39% growth compared to $117.7 million in the corresponding quarter of the previous year. ➖ Additionally, EBITDA rose from $29.6 million to $36.2 million during the latest quarter. ◉ Valuation ◉ PE Ratio ● PE vs Median PE ➖ Corcept Therapeutics sustained a median price-to-earnings ratio of 19.7x from December 2019 to 2023. ➖ Presently, with a price-to-earnings ratio of 35.3x, the stock seems to be relatively expensive. ● PE vs. Peers PE ➖ CORT's Price-To-Earnings Ratio stands at 35.3x, making it quite pricey when compared to the average of its peers, which is only 13.6x. ● PE vs. Industry PE ➖ CORT's valuation seems high, as it has a Price-To-Earnings Ratio of 35.3x, which is considerably above the US Pharmaceuticals industry average of 19x. ◉ PB Ratio ● PB vs. Peers PB ➖ The current price-to-book (P/B) ratio suggests that the stock is slightly undervalued, sitting at 7.4x compared to the peer average of 10.8x. ➖ However, it's important to note that a P/B ratio of 7.4x is typically seen as significantly overvalued. ● PB vs. Industry PB ➖ When we analyze the P/B ratio against the industry standard, CORT stands out as being notably overvalued, with its P/B ratio of 7.4x far exceeding the industry average of just 1.7x. ● PEG Ratio ➖ The stock currently seems to present a compelling investment opportunity, featuring a PEG ratio of 0.84. ◉ Cash Flow Analysis ➖ In FY23, operating cash flow increased to $127 million, compared to $120.3 million in FY22. However, it's essential to recognize that when examining the overall trend from FY19 to FY23, there has been a decline in cash flow from operations. ◉ Debt Analysis ➖ CORT operates without any debt, showcasing the robust financial health of the company. ◉ Top Shareholders ➖ Blackrock presently possesses a significant 15.8% ownership in this stock, while The Vanguard Group maintains approximately 9.1% stakes. ◉ Conclusion Following a comprehensive examination of technical and fundamental metrics, our assessment indicates that Corcept Therapeutics possesses substantial growth potential within the US biotechnology sector. Notwithstanding elevated valuations, the company's increasing research and development expenditures demonstrate a strong commitment to its future prospects. Consequently, we consider Corcept Therapeutics a prudent investment choice at this juncture.
NASDAQ:CORTLong
by NaranjCapital
SPX macro analysis ⏰ Hello 👋 it's me your RAJ 🙂 professional trader ✨ This idea 💡 is completely my own analysis to explain situation _&_ market conditions of CBOE:SPX How this chart valid for long term 📌 explained clearly based on technical #TA 📌 #DYOR Let's go with market conditions 1st 👉 PPL 📌 thinking 🤔 big crash in S&P500 , based on economy and some other theories I don't this things go , if this happens 😂 it will vanish not only stocks or companies even goverment also get vanish Money 💰 >> PPL work / save in -> gold , bank & stocks Money 💰 >> banks -> save in ->> gold , stocks & giving loan to company & PPL 📌 Money 💰 >> companies -> save in future growth 📈 give return to retailers and keep on increasing vlaue for future like NASDAQ:AAPL , NASDAQ:GOOG , NASDAQ:AMD etc .... if stocks lose 📌 PPL lose 📌 if ppl lose 📌 goverment also lose 📌 biggest revaluation 😂 This is the major index ☝️ for many stocks , did you think 🤔 it will crash 🩸 that much harder 🙂 Use 🧠 👀 Let's go with my technical analysis ⏰ #TA ->> how I am expecting macro growth 💹 👀 There tend line 🙄 at previous High 2022 > to < 2023 which actually promised trend 📉 line and even turned as resistance 📌 for 1.2yr + Finally it was broken and re-test also done 👍 turned as support 📌 💜💚 🚀 👀 According technical analysis 📌 my analysis get Invalid 📌 when month close below $3800.2 👀 There was oder block strong 🚀 support 📌 in 3 - month $4000-4200 👀 The previous order block at $4300 & $4600 easily broken 😂 These and some other theories making me push towards new high 💰 Expecting target's 🎯 🎯 :: $4880-$5018 ( easy target ) 🎯 :: $5324-$5469 ( 💯 target ) 🎯 :: $5885-$6484 ( high pressure resistance ) Support 📌 $3900-4200 This is my analysis on S&P500 on macro , i will post other patterns and chart of technical as per education under this post 📌 ----------------------------------------------------------------------------------------------------------------------------------------------------------- 🪩 disclaimer : ▶️ TQ u for supporting 💚 follow idea 💡 get updates everytime ⏰ when I updated 📌 Note 👀 👉 keeping comments , reacting with emojis , pointing us is very easy to some people They think 💬 what they see 📌 that was knowledge 📌 We need to learn market in many ways and should get adopted with experience, TECHNICAL ANALYSIS won't help understanding market structure and understanding bull 🐂 and bear 🐻 is more important Economical conditions Fundamentals Technical News Sentiments Checking macro to micro having good plan and build it is very important ☺️ Some Times market easily turn suddenly bear // bull 🤣 even we need to catch 🫴 those movements is also very important ☺️ 💛 I hope i cleared my view 🙂 if any points if I miss I will add in update 📌 post Try to understand, try to learn - try to move with flexibility with market is important Have good day 😊
SP:SPXLong
by raj5_7_5
A new US stock in our watch list: CPRT👋Hello Traders, Our 🖥️ AI system detected that there is a H4 or higher timeframe, a Breakout in CPRT for swing trade (a couple of weeks) Here is a swing trade idea (since it is near support surface, we should use small lot size) Please refer to the details Stop loss, Buy Zone,open for take profit. We are waiting for next Long setup after price discount in coming days. Boosting stock is highly risky, please do your own research on that coin before trading. For more ideas, you are welcome to visit our profile in tradingview. Have a good day! Please give this post a like if you like this kind of simple idea, your feedback will bring our signal to next better level, thanks for support!
NASDAQ:CPRTLong
by ICT_Trader_SB